58,573 Shares in Cencora, Inc. (NYSE:COR) Purchased by Quantbot Technologies LP

Quantbot Technologies LP purchased a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 58,573 shares of the company's stock, valued at approximately $14,233,000. Cencora comprises approximately 0.8% of Quantbot Technologies LP's holdings, making the stock its biggest position.

Other hedge funds have also recently added to or reduced their stakes in the company. Rise Advisors LLC acquired a new stake in Cencora in the first quarter valued at about $25,000. Legacy Bridge LLC acquired a new stake in Cencora in the first quarter valued at about $27,000. WASHINGTON TRUST Co acquired a new stake in Cencora in the first quarter valued at about $32,000. Concord Wealth Partners acquired a new stake in shares of Cencora during the 1st quarter valued at approximately $33,000. Finally, Hanson & Doremus Investment Management acquired a new stake in shares of Cencora during the 1st quarter valued at approximately $33,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Analysts Set New Price Targets

COR has been the subject of a number of research reports. SVB Leerink reiterated an "outperform" rating and set a $275.00 price target on shares of Cencora in a research report on Thursday, June 27th. Robert W. Baird lifted their price target on shares of Cencora from $280.00 to $285.00 and gave the company an "outperform" rating in a research report on Tuesday. Citigroup lifted their price target on shares of Cencora from $265.00 to $280.00 and gave the company a "buy" rating in a research report on Tuesday, April 30th. Finally, StockNews.com downgraded shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Cencora has a consensus rating of "Moderate Buy" and an average price target of $236.10.

Cencora Price Performance

Shares of Cencora stock traded up $0.52 during trading on Friday, hitting $222.52. 791,079 shares of the company were exchanged, compared to its average volume of 1,377,572. The stock has a market capitalization of $44.38 billion, a price-to-earnings ratio of 24.35, a P/E/G ratio of 1.54 and a beta of 0.45. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. Cencora, Inc. has a fifty-two week low of $171.65 and a fifty-two week high of $246.75. The firm has a 50 day moving average price of $226.65 and a 200 day moving average price of $229.26.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping the consensus estimate of $3.65 by $0.15. The firm had revenue of $68.41 billion during the quarter, compared to analysts' expectations of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. Cencora's revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $3.50 EPS. On average, equities analysts expect that Cencora, Inc. will post 13.46 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were paid a $0.51 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 annualized dividend and a yield of 0.92%. Cencora's payout ratio is currently 22.32%.

Insiders Place Their Bets

In other Cencora news, EVP Gina Clark sold 1,874 shares of Cencora stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $223.86, for a total value of $419,513.64. Following the completion of the sale, the executive vice president now directly owns 13,284 shares of the company's stock, valued at approximately $2,973,756.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the business's stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the completion of the sale, the insider now directly owns 24,418,171 shares of the company's stock, valued at approximately $5,252,836,945.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gina Clark sold 1,874 shares of Cencora stock in a transaction on Friday, May 31st. The shares were sold at an average price of $223.86, for a total transaction of $419,513.64. Following the transaction, the executive vice president now owns 13,284 shares in the company, valued at approximately $2,973,756.24. The disclosure for this sale can be found here. In the last three months, insiders sold 1,956,675 shares of company stock valued at $422,352,056. Company insiders own 15.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.